6CM
BTTX

683 Capital Management’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

683 Capital Management’s Portfolio BTTX Stock Details BTTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-259,270
Closed -$2.58M – 363
2021
Q3 		$2.58M Hold
259,270
– – 0.1% 104
2021
Q2 		$2.57M Buy
+259,270
New +$2.58M 0.09% 112

Other funds holding BTTX

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $59.6M AUM 181.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $159M AUM 139.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

683 Capital Management's BTTX Position: Q4 2021 in Review

683 Capital Management sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q4 2021, closing a stake of 259,270 shares — an estimated $2.58M sold.

683 Capital Management first reported a position in BTTX in Q2 2021 and held it in 2 quarters. The position peaked at $2.58M in Q3 2021. 20 funds tracked by Wall St. Rank hold BTTX as of Q4 2021.

  • 683 Capital Management reported no remaining Better Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • 683 Capital Management sold 259,270 Better Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $2.58M.
  • 683 Capital Management first reported a position in Better Therapeutics, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • 683 Capital Management's Better Therapeutics, Inc. Common Stock position peaked at $2.58M in Q3 2021.
  • 20 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q4 2021.

Based on 683 Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.